Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
NCT05632562Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 2024
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of O-(2-[18F]fluoroethyl)-L-tyrosine and fluoromisonidazole in high-grade glioma (HGG), sponsored by University of Alabama at Birmingham. Primary endpoint: Detection of viable glioma based on PET up to 24 months. Started Mar 2024; status: recruiting.
02
Drugs
O-(2-[18F]fluoroethyl)-L-tyrosinefluoromisonidazole
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT05632562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632562.